The following articles are being highlighted as part of Circulation's Topic Review series. This series will summarize the most important manuscripts, as selected by the editors, published in Circulation and the Circulation subspecialty journals. The studies included in this article represent the most read manuscripts published on the topic of molecular cardiology within the last year. (Circulation. 2013;128:e88-e99.) The Editors
Hypoxia Induces Myocardial Regeneration in Zebrafish
Summary-Cardiac ischemia leads to a reduction in oxygen supply and subsequent induction of hypoxia. At present, the consensus is that the hypoxia associated with cardiac ischemia initially induces a cardioprotective response; however, prolonged exposure ultimately leads to necrosis and loss of myocardial tissue. Treatment of patients who have suffered an ischemic episode aims to reduce hypoxia. Our data now indicate that hypoxia could also play a beneficial role. We have found that hypoxia positively regulates myocardial regeneration in zebrafish. We have also found that some of the processes that are regulated by hypoxia during zebrafish heart regeneration have also been reported in mammals/humans after cardiac ischemia. In particular, we have observed that hypoxia induces zebrafish cardiomyocytes to dedifferentiate, a process that is also associated with cardiomyocytes in ischemic patients. Unfortunately, although they are capable of this initial dedifferentiation, human cardiomyocytes fail to proliferate and subsequently regenerate the heart. Future strategies attempting to regenerate a damaged human heart should take into account that hypoxia can play a beneficial role in inducing a regenerative response.
Conclusions-These results indicate that hypoxia plays a positive role during heart regeneration, which should be taken into account in future strategies aimed at inducing heart regeneration in humans. 1 
CKIP-1 Inhibits Cardiac Hypertrophy by Regulating Class II Histone Deacetylase Phosphorylation Through Recruiting PP2A
Summary-Among the intracellular signaling pathways involved in the regulation of cardiac hypertrophy, class II histone deacetylases (HDACs) have been identified as important signal-responsive repressors for cardiac hypertrophy. Little is known about the regulation of HDAC4 in response to extracellular stimuli leading to cardiac hypertrophy. Here we identified casein kinase-2 interacting protein-1 (CKIP-1) as a novel regulator of pathological cardiac hypertrophy and class II HDACs/myocyte enhancer factor-2 signaling in cardiac myocytes. In this research, our data showed that CKIP-1 is induced early after pressure overload, but sharply reduced in the late phases of cardiac hypertrophy in mouse and human hearts. CKIP-1 systemically deficient mice exhibit spontaneous pathological cardiac hypertrophy by 8 months and display exaggerated responses to pressure overload. Conversely, cardiac specific overexpression of CKIP-1 attenuates pathological remodeling during chronic pressure overload. HDAC4 was identified to be a CKIP-1 interaction partner through unbiased interaction screening. HDAC4 is involved in the regulation of myocyte enhancer factor-2 transcription activity via decreasing the phosphorylation of HDAC4. CKIP-1 could increase the association of HDAC4 with protein phosphatase 2A and promote the dephosphorylation of HDAC4. These results demonstrated that CKIP-1 was required to inhibit the occurrence of cardiac hypertrophy and represented a promising candidate target for preventing hypertrophic cardiomyopathy.
Conclusions-CKIP-1 was found to be an inhibitor of cardiac hypertrophy by upregulating the dephosphorylation of HDAC4 through the recruitment of protein phosphatase 2A. These results demonstrated a unique function of CKIP-1, by which it suppresses cardiac hypertrophy through its capacity to regulate HDAC4 dephosphorylation and fetal cardiac genes expression. 2
Endothelial Nuclear Factor-κB-Dependent Regulation of Arteriogenesis and Branching
Summary-Collateral circulation plays a protective role in case of an ischemic insult precipitated by the occlusion of an arterial vessel. Despite their presumed physiological and clinical importance, little is known about the manner in which collaterals develop. A thorough understanding of this process is important to any attempts at therapeutic arteriogenesis. Collaterals are thought to arise either by expansion from the preexisting vessels or by de novo growth. In either case, the key stimulus is probably mechanical in nature, such as shear stress, and not tissue ischemia per se. One well-understood signaling mechanism that controls the size and density of a vascular network is the Delta/Notch pathway. A number of studies have demonstrated that activation of Notch-1 by its ligand δ-like ligand 4 (Dll4) leads to a decrease in vascular branching. However, the link between Dll4/ Notch signaling and shear stress has not been established. Endothelial shear stress activates the transcription factor nuclear factor-κB, which controls expression of a broad array of genes involved in cell adhesion and migration. In this study, we unexpectedly show that Dll4 expression is critically dependent on nuclear factor-κB, likely via nuclear factor-κB-dependent stabilization of hypoxia-inducible factor-1 and -2 genes. In the absence of endothelial nuclear factor-κB activation, reduced Dll4 levels lead to a much greater expansion in collateral growth than seen under normal circumstances. Paradoxically, that leads to a severe impairment in tissue blood flow. Thus, although increasing collateral density is a worthy therapeutic goal, the quality of the collateral network is just as important as its size.
The Angiogenic Factor Secretoneurin Induces Coronary Angiogenesis in a Model of Myocardial Infarction by Stimulation of Vascular Endothelial Growth Factor Signaling in Endothelial Cells
Summary-Our work shows that the angiogenic factor secretoneurin improves left ventricular function in an animal model of myocardial infarction. Secretoneurin stimulates angiogenesis and arteriogenesis in the infarct border zone and reduces scar size after the infarct. Mechanistically, secretoneurin exerts beneficial effects on coronary endothelial cells via stimulation of growth factor receptors for angiogenic cytokines such as vascular endothelial growth factor or fibroblast growth factor. Secretoneurin thereby stimulates binding of vascular endothelial growth factor to its coreceptors neuropilin-1 and heparan sulfate proteoglycans. Despite promising preclinical and early clinical data for the application of angiogenic cytokines in the treatment of ischemic heart or limb disease (a therapeutic strategy termed therapeutic angiogenesis), randomized phase III clinical trials (Angiogenic GENe Therapy [AGENT] trial for coronary heart disease, Therapeutic Angiogenesis for Management of Arteriopathy in a Randomized International Study [TAMARIS] for critical limb ischemia) did not show the expected results. In addition to patient and study end point selection and pharmacokinetic issues, it is also conceivable that administration of a single angiogenic factor is not sufficient to orchestrate a complex biological event like the growth of a new blood vessel. Indeed, a combination of angiogenic growth factors (such as basic fibroblast growth factor and platelet-derived growth factor or basic fibroblast growth factor and hepatocyte growth factor) exerted more potent and long-lasting angiogenic responses and beneficial effects in ischemic diseases compared with administration of single factors. In this context, it is of particular interest that secretoneurin, as a single compound, stimulated receptors for several of these cytokines like vascular endothelial growth factor or fibroblast growth factor. We therefore think that secretoneurin may be a promising candidate for therapeutic angiogenesis.
Conclusions-Our data show that secretoneurin acts as an endogenous stimulator of vascular endothelial growth factor (VEGF) signaling in coronary endothelial cells by enhancing binding of VEGF to low-affinity binding sites and neuropilin-1 and stimulates further growth factor receptors like fibroblast growth factor receptor-3. Our in vivo findings indicate that secretoneurin may be a promising therapeutic tool in ischemic heart disease. 4
Pathological Role of Serum-and Glucocorticoid-Regulated Kinase 1 in Adverse Ventricular Remodeling
Summary-Patients with heart failure have an increased risk of ventricular arrhythmias and sudden cardiac death. Heart failure is associated with changes in the electric properties of the heart that form the triggers and substrate for ventricular arrhythmias. Available antiarrhythmic drugs have not shown any clinical benefit in patients with heart failure and have significant proarrhythmic side effects. To gain a better understanding of mechanisms that underlie the electric changes in heart failure, we focused on the serum-and glucocorticoid-regulated kinase-1 (SGK1), a component of the cardiac phosphatidylinositol 3-kinase signaling pathway that is activated in heart failure. Our results demonstrated that activation of SGK1 in the heart increased mortality, cardiac dysfunction, and ventricular arrhythmias. The proarrhythmic effects of SGK1 were linked to biochemical and functional changes in the cardiac sodium channel and could be reversed by treatment with ranolazine, a blocker of the late sodium current. Conversely, inhibition of SGK1 in the heart protected against fibrosis, heart failure, and sodium channel alterations after hemodynamic stress. Our studies highlight the importance of sodium flux in the pathogenesis of arrhythmia in heart failure and raise the possibility that drugs that block the late sodium current could be useful in this setting. Moreover, these results identify SGK1 as a novel kinase target for treatment of both arrhythmia and cardiac dysfunction. The potential clinical importance of this observation is underscored by the therapeutic success of kinase inhibitors in other disease processes.
Conclusions-SGK1 appears both necessary and sufficient for key features of adverse ventricular remodeling and may provide a novel therapeutic target in cardiac disease. 5
Cardiomyogenesis in the Aging and Failing Human Heart
Summary-For the last 70 years, the possibility that the adult heart retains after birth a significant capacity for myocyte regeneration has been opposed strongly. Similarly, the notion that stem cells reside within the myocardium and regulate tissue homeostasis physiologically and the repair process after injury has been challenged. Different approaches have provided contrasting results, which have divided the scientific community into supporters of an extremely low myocyte renewal in the mammalian heart and proponents of a relatively high myocyte replacement at all stages of life. Essentially, 2 opposite views are currently being purported: one that sees the heart as a static organ, characterized by a large number of myocytes that are present at birth and live as long as the organ and organism, and the other that considers the heart a highly dynamic organ in which the myocyte compartment is restored several times during the course of life. With retrospective 14C birth dating of cells, it has been possible to demonstrate that the human heart retains a significant degree of myocyte regeneration throughout life and in the presence of chronic heart failure. Although the ability to regenerate cardiomyocytes and vascular structures cannot prevent the manifestations of myocardial aging or oppose the negative effects of ischemic and idiopathic dilated cardiomyopathy, understanding the complex mechanisms of tissue repair may identify novel strategies for the management of chronic heart failure and prolong health span and lifespan in the elderly.
Conclusions-
The human heart is a highly dynamic organ that retains a remarkable degree of plasticity throughout life and in the presence of chronic heart failure. However, the ability to regenerate cardiomyocytes, vascular endothelial cells, and fibroblasts cannot prevent the manifestations of myocardial aging or oppose the negative effects of ischemic and idiopathic dilated cardiomyopathy. 6
Homeostatic and Tissue Reparation Defaults in Mice Carrying Selective Genetic Invalidation of CXCL12/Proteoglycan Interactions
Summary-CXCL12 regulates with unchallenged capacity both the tissue homing and survival of circulating tissue-specific progenitors, hematopoietic cells, and bone marrow stem cells and triggers inflammatory cell infiltration. Beyond the binding to its cognate receptor CXCR4, we speculate that the interaction of CXCL12 with proteoglycans, particularly heparan sulfate, enables the formation of chemokine gradients that determine the orientated migration and tissue recruitment of circulating cells. We engineered a mouse carrying a Cxcl12 gene (Cxcl12Gagtm) mutation that precludes interactions with heparan sulfate structures while not affecting CXCR4-dependent cell signaling of CXCL12 isoforms. After induced acute ischemia, a marked impaired capacity to support revascularization was observed in Cxcl12Gagtm/Gagtm animals associated with a reduced number of infiltrating cells in the ischemic tissue. Of interest, Cxcl12γ was the most abundant isoform in both the normal and ischemic muscle. Importantly, exogenous administration of CXCL12γ, which binds heparan sulfate with the highest affinity ever reported for a cytokine, fully restored vascular growth, whereas heparan sulfate-binding CXCL12γ mutants failed to promote revascularization in Cxcl12Gagtm/Gagtm animals. In terms of the potential of CXCL12 in regenerative medicine, the continuous delivery or administration in an immobilized form of CXCL12α is required to provide therapeutic effect in postischemic treatment. CXCL12γ could overcome this limitation, thus efficiently activating the proangiogenic mechanisms. The findings presented here pave the way for investigating the contribution of CXCL12/heparan sulfate interactions to other homeostatic and physiopathological functions played by this unique chemokine and could eventually have broad relevance for other chemokine systems.
Conclusions-These findings prove the role played by heparan sulfate interactions in the functions of CXCL12 in both homeostasis and physiopathological settings and document for the first time the paradigm of chemokine immobilization in vivo. 7
Therapeutic Impact of Follistatin-Like 1 on Myocardial Ischemic Injury in Preclinical Models
Summary-Heart tissue secretes a variety of bioactive molecules, also known as cardiokines, that modulate the cellular processes in the heart. Follistatin-like 1 (FSTL1) is a cardiokine that is upregulated in the heart in response to ischemic insult. In the present study, we investigated the therapeutic impact of FSTL1 on acute cardiac injury in small and large preclinical animal models of ischemia/reperfusion. Systemic delivery of recombinant human FSTL1 protein to mice led to reductions of myocardial injury and dysfunction. Furthermore, intracoronary injection of human FSTL1 protein attenuated myocardial infarction and improved cardiac function in pigs after ischemia/ reperfusion. The beneficial actions of FSTL1 were associated with suppression of apoptosis and inflammation in the ischemic heart. FSTL1 promoted AMP-activated protein kinase signaling pathways in the ischemic heart, thereby leading to a reduction of inflammation and apoptosis. FSTL1 also antagonized the proinflammatory and proapoptotic functions of bone morphogenetic protein-4. Therefore, FSTL1 can prevent myocardial ischemia/reperfusion injury by inhibiting apoptosis and inflammatory response through modulation of AMP-activated protein kinase-and bone morphogenetic protein-4-dependent mechanisms. Our observations suggest that FSTL1 could represent a novel therapeutic target for the treatment of postmyocardial infarction, acute coronary syndrome.
Conclusions-Our data indicate that FSTL1 can prevent myocardial ischemia/reperfusion injury by inhibiting apoptosis and inflammatory response through modulation of AMP-activated protein kinase-and bone morphogenetic protein-4-dependent mechanisms, suggesting that FSTL1 could represent a novel therapeutic target for postmyocardial infarction, acute coronary syndrome. 8
Myocardial Notch Signaling Reprograms Cardiomyocytes to a Conduction-Like Phenotype
Summary-Conduction disorders are a significant cause of morbidity and mortality, often requiring implantation of electronic pacemakers to coordinate activation of the heart. Although pacemaker technology is quite advanced, there are important limitations to electronic devices in comparison with native conduction tissues. Cellular-based replacement strategies and regenerative approaches for the treatment of several cardiac diseases, including heart failure, are currently being tested in animals and humans. One such strategy involves reprogramming, or converting 1 cell type into another cell type. We provide evidence that a single factor, Notch, is capable of reprogramming cardiomyocytes into Purkinje-like conduction cells both in vivo and in vitro. Notch activation produces changes in gene expression and cellular electrophysiology in cardiomyocytes as late as the perinatal period. The ability to manipulate cardiomyocyte cell fate toward cells of the conduction lineage may enable development of therapies to replace or augment electronic pacemakers in individuals with conduction disorders.
Conclusions-Notch can instruct the differentiation of chamber cardiac progenitors into specialized conduction-like cells. Plasticity remains in late-stage cardiomyocytes, which has potential implications for engineering of specialized cardiovascular tissues. 9
Loss of Perivascular Adipose Tissue on Peroxisome Proliferator-Activated Receptor-γ Deletion in Smooth Muscle Cells Impairs Intravascular Thermoregulation and Enhances Atherosclerosis
Summary-Recent confirmation that in addition to white adipose tissue, brown adipose tissue (BAT) is found in adult humans, where it plays a distinct role in adaptive thermoregulation and energy metabolism, has sparked active research on adipose tissues as bioactive organs, mostly focusing on their pathophysiological aspects for treatment of metabolic disorders. This revival led to the recognition of perivascular adipose tissue (PVAT) not just as a support structure but rather as a biologically active regulatory component of the vasculature. Despite increased understanding of PVAT autocrine and paracrine vascular roles, there is a paucity of knowledge regarding its involvement in atherosclerosis. PVAT shares some characteristics with BAT, but to date, its specific roles remain obscure because of limited animal models. We present experimental proteomics evidence that in vivo chronic cold stimulus results in activation of PVAT characterized by cellular metabolic pathways shared with BAT. A peroxisome proliferator-activated receptor-γ-knockout strategy targeting smooth muscle cells results in loss of PVAT surrounding the vasculature. Use of this unique model in combination with our newly developed surgical removal of BAT reveals, for the first time, robust atheroprotection mediated by adaptive thermogenic activation of PVAT in chronic cold adaptation associated with a reduction of plasma lipid profiles and improvement of the endothelial dysfunction. Endothelial protective effects likely result from increased prostacyclin release by activated PVAT. Thus, we uncovered a new paradigm that directly links PVAT to the beneficial effects of cold exposure and thermogenesis in atherosclerosis likely to mimic those observed in humans.
Conclusions-PVAT is a vasoactive organ with functional characteristics similar to BAT and is essential for intravascular thermoregulation of cold acclimation. This thermogenic capacity of PVAT plays an important protective role in the pathogenesis of atherosclerosis. 10
Myocardial CXCR4 Expression Is Required for Mesenchymal Stem Cell Mediated Repair Following Acute Myocardial Infarction
Summary-The growing success for the treatment of acute myocardial infarction has led to an increasing prevalence of chronic heart failure. Multiple stem cell populations are under investigation, and, in general, most demonstrate some modest benefit and the potential to improve outcomes of patients with acute myocardial infarction and chronic heart failure. The majority of data suggest that adult stem cells do not induce regeneration of the cardiac myocytes; rather, studies have demonstrated that adult stem cell therapy induces endogenous stem cell-based myocardial repair. One of the important pathways activated by adult stem cells is the SDF-1:CXCR4 axis. The importance of these finds are highlighted by a recently completed multicenter phase I clinical trial demonstrating the safety and efficacy of the endoventricular delivery of plasmid DNA encoding hSDF-1 in patients with New York Heart Association class III chronic heart failure at 4 and 12 months after treatment (http://www.clinicaltrials. gov, NCT01082094). Although SDF-1 has been shown to be critical in myocardial repair post-MI, the relative importance of cardiac stem cell CXCR4 and CM-CXCR4 expression on mesenchymal stem cellbased myocardial repair remains unanswered. Using our novel model of CM-CXCR4 null mice, we dissected the effects of mesenchymal stem cell SDF-1 expression on end-organ tissue repair and demonstrated a critical role for cardiac progenitor cell and cardiac myocyte CXCR4 expression on mesenchymal stem cell -mediated cardiac repair. These findings are the first to define a specific paracrine factor of critical importance in adult stem cell therapy and will directly affect development of stem cell and paracrine factor strategies for the prevention and treatment of cardiac dysfunction in patients with acute myocardial infarction and chronic heart failure.
Conclusions-These data demonstrate that the local trophic effects of MSC require cardiac progenitor cell and CM-CXCR4 expression and are mediated by MSC stromal cell-derived factor-1 secretion. Our results further demonstrate and quantify for the first time a specific paracrine mechanism of MSC engraftment. In the absence of CM-CXCR4 expression, there is a significant loss of functional benefit in MSC-mediated repair despite equal increases in vascular density. 11
Nitrite Regulates Hypoxic Vasodilation via Myoglobin-Dependent Nitric Oxide Generation
Summary-Emerging evidence implicates that inorganic nitrite provides a source for bioactive nitric oxide (NO·). Nitrite is reduced to NO· under circumstances with decreased O2 or pH levels along physiological gradients or under pathological conditions. Hypoxic vasodilation is a physiological response to low O2 tension, and the present data elucidate a pivotal in vivo role for endogenous nitrite in vascular responsiveness. Although exogenous nitrite supplementation has been associated previously with tissue protection in preclinical disease models (eg, myocardial infarction and several other local and general pathological conditions), the underlying mechanisms for the reduction of endogenous nitrite remained incompletely understood. We provide evidence for a crucial role for the endogenous nitrite/myoglobin pathway in this response. Ablation of vascular myoglobin in myoglobin-deficient mice impaired the reduction of exogenous and endogenous nitrite to NO·, which subsequently caused an extenuated ex vivo and in vivo vasodilatory response under hypoxia. Enhancing the endogenous nitrite levels via administration of nitrite or other NO· sources may therefore provide beneficial effects in a wide variety of cardiovascular diseases but also points to a potential role of nitrite in other tissues where myoglobin has been located recently. We speculate that increased myoglobin concentrations, as occur during physical exercise training, may further enhance nitrite-dependent signaling. These findings both provide insight into physiological mechanisms and point to a tractable therapeutic strategy in which nitrite is used as a site-selective vasodilator to circumvent the potentially deleterious effects observed with unselective substances (eg, organic nitrates).
Conclusions-Endogenous nitrite is a physiological effector of hypoxic vasodilation. Its reduction to NO· via the heme globin myoglobin enhances blood flow and matches O2 supply to increased metabolic demands under hypoxic conditions. 12
Endothelial Cell-Specific FGD5 Involvement in Vascular Pruning Defines Neovessel Fate in Mice
Summary-The capacity of endothelial cells in the vasculature to regenerate in human adults depends largely on the same molecular pathways that regulate the process of angiogenesis during embryonic development. Growth of neovessel not only is determined by the availability of growth factors such as vascular endothelial growth factor-A but also depends on the ability of the neovascular structure to maintain stability while excess vessel structures are actively removed by a biological mechanism called vascular pruning. In this article, a novel factor named FYVE, RhoGEF, and PH domain-containing 5 (FGD5) was discovered to be involved in active regulation of this pruning process. A better understanding of the molecular pathways that govern vascular pruning could benefit patient treatment in therapies in which stimulation of vascular growth is desired and in which this type of regulation should be adapted.
Conclusions-We have identified FGD5 as a novel genetic regulator of vascular pruning by activation of endothelial cell-targeted apoptosis. 13

C1q/Tumor Necrosis Factor-Related Protein-3, a Newly Identified Adipokine, Is a Novel Antiapoptotic, Proangiogenic, and Cardioprotective Molecule in the Ischemic Mouse Heart
Summary-Cardiovascular disease remains a leading cause of mortality worldwide. Although improved reperfusion strategies have led to declined death rates after acute myocardial infarction, both the incidence and prevalence of post-myocardial infarction heart failure have continually increased in recent years. As a result of the increased incidence of diabetes mellitus and its association with heart failure, there is now great interest in elucidating the underlying molecular mechanisms linking these pathologies. Considerable evidence exists that the majority of adipokines (including tumor necrosis factor [TNF]-α, leptin, plasminogen activator inhibitor type 1, transforming growth factor-β, and resistin) adversely regulate myocardial metabolism, cardiomyocyte hypertrophy, extracellular matrix structure and composition, and cell death. The present study demonstrated that C1q/TNF-related protein-3 (CTRP3), a key member of a newly identified adipokine family, exerts cardiac actions opposing the majority of other adipokines and is a novel and potent cardioprotective molecule. Expression and production of CTRP3 are significantly reduced e92 Circulation August 13, 2013
after myocardial infarction, and replenishment of CTRP3 protects the heart by attenuating postischemic pathological remodeling and promoting cardiomyocyte-endothelial cell communication. These results suggest that the balance between cardioprotective and cardioharmful cytokines tilts during pathological conditions such as heart failure. Interventions restoring the balance may represent a novel therapeutic strategy in the treatment of cardiovascular diseases, particularly in those patients with diabetes mellitus.
Conclusions-CTRP3 is a novel antiapoptotic, proangiogenic, and cardioprotective adipokine, the expression of which is significantly inhibited after myocardial infarction. 14
Impaired Autophagosome Clearance Contributes to Cardiomyocyte Death in Ischemia/Reperfusion Injury
Summary-In myocardial infarction resulting from coronary occlusion, contemporary therapy is focused on expedient reperfusion to prevent loss of myocardium. Despite reperfusion and often as a result of reperfusion injury, there is ongoing cardiomyocyte cell death, which can be targeted therapeutically to maximize myocardial salvage. Autophagy is an evolutionarily conserved lysosomal pathway to break down damaged cellular constituents, to provide nutrients, and to facilitate cell survival. Autophagy has also been implicated as a mechanism for programmed cell death. In cardiac ischemia/ reperfusion injury, autophagy is upregulated, and previous studies have suggested that it plays a dichotomous role in facilitating cell survival during ischemia but provoking cell death during reperfusion.
To examine the hypothesis that autophagy is upregulated in reperfusion injury but impaired, thus preventing its prosurvival function, we have carefully examined flux through the autophagy pathway in cardiomyocytes subjected to ischemia and reperfusion. Our results demonstrate that autophagosomes accumulate during reperfusion injury after myocardial ischemia, suggesting impaired autophagosome processing. This accumulation of autophagosomes, presumably with the deleterious cargo that is not degraded, is associated with an increased prevalence of reactive oxygen species and mitochondrial permeabilization, resulting in necrotic cardiomyocyte death. The underlying mechanism for the impairment in autophagosome processing appears to be a reperfusion-induced decline in lysosome-associated membrane protein-2 levels, a protein critical for autophagosome-lysosome fusion, and an increase in the abundance of BECLIN-1. Restoring lysosome-associated membrane protein-2 levels and knocking down BECLIN-1 restore autophagosome processing with the attenuation of cell death. Thus, facilitating autophagy with enhanced flux through the autophagy pathway is a promising strategy to achieve myocardial salvage in ischemia/reperfusion injury.
Conclusions-Ischemia/reperfusion injury impairs autophagosome clearance mediated in part by reactive oxygen speciesinduced decline in lysosome-associated membrane protein-2 and upregulation of BECLIN-1, contributing to increased cardiomyocyte death. 15
A Novel Regulator of Macrophage Activation: miR-223 in Obesity-Associated Adipose Tissue Inflammation
Summary-Macrophage-mediated adipose tissue inflammation is a major contributor to the pathogenesis of obesity-associated chronic diseases, including the 2 types of most prevailing diseases, namely type 2 diabetes mellitus and cardiovascular diseases. The activation status of macrophages is a key determinant for the onset of these diseases, and despite extensive research in this area, major questions about macrophages function and their interactions with host tissues remain unanswered. The discovery of microRNAs (miRNAs) has opened a new window for understanding the regulatory networks related to homeostasis and disease. MiRNAs are a family of small noncoding RNAs that have been demonstrated to be crucial regulators in multiple physiological processes and disease pathogenesis. Altered expression patterns of miRNAs are tightly associated with chronic inflammatory diseases. However, miRNA-mediated regulatory networks in modulating macrophage polarization in adipose tissue inflammation have not been previously investigated. In this study, we demonstrated that miR-223 is a novel and crucial regulator of macrophage polarization and is indicated for suppressing proinflammatory and enhancing anti-inflammatory responses. Our results identify a new miRNA-based paradigm for the regulation of insulin sensitivity and provide the basis for using miRNA analogs to treat insulin resistance-related diseases.
Conclusions-For the first time, this study demonstrates that miR-223 acts to inhibit Pknox1, suppressing proinflammatory activation of macrophages; thus, it is a crucial regulator of macrophage polarization and protects against diet-induced adipose tissue inflammatory response and systemic insulin resistance. 16
Lack of Microsomal Prostaglandin E2 Synthase-1 in Bone Marrow-Derived Myeloid Cells Impairs Left Ventricular Function and Increases Mortality After Acute Myocardial Infarction
Summary-Millions of patients use nonsteroidal anti-inflammatory drugs (NSAIDS) to treat pain and inflammatory disorders. NSAIDS block the activity of cyclooxygenase-2 (COX-2), an enzyme that catalyzes the second of three steps in prostaglandin biosynthesis. Unfortunately, some COX-2 inhibitors are associated with an increased risk of myocardial infarction (MI) and stroke, possibly because of decreased production of antithrombotic eicosanoids, such as PGI2, combined with simultaneous unopposed production of prothrombotic thromboxane A2, an eicosanoid catalyzed via COX-1 in platelets. Microsomal prostaglandin E 2 synthase-1 (mPGES-1) is downstream from COX-2 in the inducible PGE2 biosynthetic pathway. Inhibition or deletion of mPGES-1 decreases pain, fever and inflammation without increasing the propensity for thrombosis. Therefore, pharmacological inhibitors of mPGES-1 may be a viable replacement for COX-2 inhibitors, and may not be associated with an increased risk of thrombotic cardiovascular events. We show that targeted deletion of mPGES-1 in bone marrow derived leukocytes that are recruited to the heart leads to left ventricular (LV) dilation, impaired LV systolic and diastolic function, adverse LV remodelling, and increased mortality after MI. These finding increase our understanding of the molecular events that control LV remodeling after MI, and demonstrate the importance of eicosanoid biosynthesis by inflammatory leukocytes in this process. However, caution is warranted in extrapolating the results of targeted deletion of mPGES-1 in bone marrow derived leukocytes in mice to the possible outcome of pharmacological inhibition of mPGES-1 in clinical practice. Further studies, of mice and humans, are warranted to define the role of mPGES-1 in LV remodeling after MI.
Conclusions-Lack of mPGES-1 in bone marrow-derived leukocytes negatively regulates COX-1 expression, prostaglandin E2 biosynthesis, and inflammation in the infarct and leads to impaired LV function, adverse LV remodeling, and decreased survival after acute myocardial infarction. 17
Human Genome-Wide Association and Mouse Knockout Approaches Identify Platelet Supervillin as an Inhibitor of Thrombus Formation Under Shear Stress
Summary-Platelets play a central role in ischemic arterial vascular disease, and antiplatelet therapies are mainstays of treatment. The findings in this study identify a novel platelet protein, supervillin, which functions to dampen the early formation of platelet thrombi under high shear stress. Although these results will not alter current management of vascular disease, there are potential clinical implications. Supervillin is an interaction hub for many proteins that regulate cell adhesion and contractility. Drug targeting of supervillin or one of its binding partners in a manner that would decrease platelet adhesion under high shear forces may have antithrombotic benefit for arterial vascular diseases such as myocardial infarction and stroke. This benefit could be especially pronounced in African Americans, who suffer disproportionately from cardiovascular disease. Conversely, drugs that knowingly or unknowingly block supervillin function in platelets could have untoward effects of promoting thrombosis. The shear dependence of the supervillin effect presents an opportunity to develop therapies that differentially affect arterial and venous thrombosis by inhibiting platelet thrombus formation under high shear settings (eg, acute coronary syndromes or percutaneous coronary intervention) without altering the normal hemostatic function of platelets in low-shear veins or microcirculation. Finally, single-nucleotide polymorphisms strongly linked to the causative supervillin variant may be useful as a biomarker for risk of thrombosis or hemorrhage.
Conclusions-We show for the first time that (1) platelets contain supervillin; (2) platelet thrombus formation in the PFA-100 is associated with human SVIL variants and low SVIL expression; and (3) murine platelets lacking supervillin exhibit enhanced platelet thrombus formation at high shear stress. These data are consistent with an inhibitory role for supervillin in platelet adhesion and arterial thrombosis. 18
Targeted Deletion of MicroRNA-22 Promotes Stress-Induced Cardiac Dilation and Contractile Dysfunction
Summary-The identification of genes and pathways involved in progression to heart disease is a major challenge and focus in cardiac research. New evidence has established the importance of microRNAs (miRNAs) in controlling cardiac pathophysiology. The relevance of miR-22 to human heart failure has been suggested by the recent demonstration that miR-22 expression was either downregulated or upregulated in human dilated cardiomyopathy and diseased hearts. In the present report, we demonstrate that genetic ablation of the non-protein-coding gene miR-22 in mice impairs cardiac reserve to β-adrenergic stimulation with dobutamine. Here, we show that the absence of miR-22 increases vulnerability to pressure-overload-induced cardiac decompensation characterized by left ventricular dilation and loss of contractile function.The inability of mutant mice to adapt to biomechanical stress was caused in part by restrained expression of genes such as sarcoplasmic reticulum calcium ATPase (Serca2a), LIM domain binding 3 (Ldb3), cardiac LIM protein (Csrp3/Mlp), and Titin encoding calcium handling and other contractile/myofibrillar proteins implicated in human dilated cardiomyopathy. This phenotype was attributed in part to inappropriate inhibition of serum response factor-dependent gene expression in mutant hearts. In addition, we demonstrated that miR-22 inhibits the expression of purine-rich element binding protein B, a transcription factor that opposes control of sarcomeric/cardiac expression by serum response factor. These results demonstrate the importance of miR-22 as a homeostatic keeper of cardiac gene expression and modulator of cardiac contractile reserve to acute and hemodynamic stress. These results are the first to demonstrate a novel disease mechanism of cardiac pathogenesis involving miR-22.
Conclusions-These data indicate that miR-22 functions as an integrator of Ca2+ homeostasis and myofibrillar protein content during stress in the heart and shed light on the mechanisms that enhance propensity toward heart failure. 19
Cardioprotection Through S-Nitros(yl)ation of Macrophage Migration Inhibitory Factor
Summary-Macrophage migration inhibitory factor (MIF) is the first identified cytokine, discovered almost half a century ago by David, Bloom, and Bennett. Molecular knowledge about this protein mediator has recently grown tremendously, and a pivotal role has been attributed to MIF as a key regulator of innate and acquired immunity, as well as numerous pathophysiological functions involving its inflammatory cytokine and chemokine. There is emerging evidence that MIF also plays a Conclusions-S-nitros(yl)ation of MIF is a pivotal novel regulatory mechanism, providing enhanced activity resulting in increased cytoprotection in myocardial reperfusion injury. 20
Role for Substance P-Based Nociceptive Signaling in Progenitor Cell Activation and Angiogenesis During Ischemia in Mice and in Human Subjects
Summary-Pain and inflammation are generally thought of as medical problems. Treatment of these defense responses is routine in patients with myocardial and peripheral ischemia. However, blocking a defense can be harmful. It has been shown that taking nonsteroidal anti-inflammatory drugs can increase a person's risk of having a heart attack or stroke. Furthermore, morphine has been associated with higher mortality in patients with acute coronary syndrome. The present study provides novel insight into the role of the pain mediator substance P in vascular regeneration by bone marrow-derived stem cells. After ischemic injury, substance P is released from central terminals projecting to distinct brain stem centers, thus contributing to pain perception and pain-induced reactions, as well as from sensory fibers innervating the myocardium, leading to local neurogenic e94 Circulation August 13, 2013
inflammation. In the present study, we show that substance P also contributes to mobilize stem cells from the bone marrow and to recruit them to the infarcted heart. Bone marrow cells attracted by substance P are able to promote neovascularization, thereby accelerating the healing of ischemic tissues. Conversely, genetic abrogation of substance P signaling or pharmacological inhibition of substance P release by morphine results in attenuation of both stem cell mobilization and reparative vascularization in models of ischemia. These new findings may have important clinical implications for tailoring new regenerative treatments based on stem cell recruitment by pain mediators. Nonetheless, the nociceptive signaling is also used in other biological contexts in which pain is not operant. Therefore, additional work is warranted to refine new therapeutic strategies compatible with pain relief and cardiovascular repair.
Conclusions-Our data highlight the role of SP in reparative neovascularization. Nociceptive signaling may represent a novel target of regenerative medicine. 21
Regulation of Cardiac MicroRNAs by Bone Marrow Mononuclear Cell Therapy in Myocardial Infarction
Summary-Cell-based therapy is a promising option to treat cardiovascular diseases. Multiple mechanisms have been proposed to mediate the therapeutic benefits of bone marrow-derived mononuclear cell therapy, including cell transdifferentiation, cell fusion, and the release of paracrine growth factors and cytokines. In fact, various cytokines and growth factors from transplanted progenitor cells have been shown to elicit positive effects by influencing cardiomyocyte survival, angiogenesis, and the recruitment of endogenous stem cells. MicroRNAs are small noncoding RNAs that negatively modulate gene expression by inhibiting protein translation or inducing degradation of the targeted mRNA. MicroRNAs play an important role in biological processes during development, tissue homeostasis, and disease. Several microRNAs are regulated after the induction of myocardial infarction and control neovascularization and fibrosis. Here, we demonstrate that the paracrine regulation of cardiac microRNAs by transplanted bone marrowderived mononuclear cells contributes to the protective effects of cell therapy. In particular, bone marrow-derived mononuclear cell release insulin-like growth factor-1, which inhibits the processing of miR-34a, thereby blocking cardiomyocyte apoptosis. Insulin-like growth factor-1-mediated inhibition of miR-34a may contribute to several of the known cardioprotective functions of insulin-like growth factor-1.
Conclusions-Together, our data demonstrate that the paracrine regulation of cardiac miRNAs by transplanted bone marrow cells (BMCs) contributes to the protective effects of cell therapy. BMCs release IGF-1, which inhibits the processing of miR-34a, thereby blocking cardiomyocyte apoptosis. 22
Activation of CD4+ T Lymphocytes Improves Wound Healing and Survival After Experimental Myocardial Infarction in Mice
Summary-Myocardial infarction is the leading cause of chronic heart failure syndrome, which still causes tremendous morbidity and mortality in the Western world. After myocardial infarction, heart failure results not only from a loss of contractile tissue but also from the remodeling of the remaining viable myocardium. Adverse remodeling often occurs despite optimal medical therapy and might originate from early dysfunctional wound healing. The pivotal role of activation of innate immunity during wound healing and remodeling of the remote myocardium after myocardial infarction has long been recognized. In this study, we present the first experimental data indicating that myocardial infarction induces activation of T lymphocytes. In particular, CD4+ T cells become activated on recognition of self-antigens during myocardial infarction and infiltrate both the infarcted and remote myocardium. CD4+ T-cell activation improves both wound healing and clinical outcome, because the genetically determined absence or inability of CD4+ T cells to recognize autoantigens results in impaired wound healing and impaired survival after myocardial infarction. Impaired collagenous scar formation is the most evident underlying cause of the clinical phenotype when CD4+ T cells are lacking or their activation is hampered. Our results might thus pave the way for the development of novel therapeutic protocols to modulate the adaptive immune response to myocardial injury.
Conclusions-
The present study provides the first evidence that CD4+ T cells become activated after myocardial infarction, presumably driven by recognition of cardiac autoantigens, and facilitate wound healing of the myocardium. 23
Endothelial Cells Overexpressing Interleukin-8 Receptors Reduce Inflammatory and Neointimal Responses to Arterial Injury
Summary-The endothelium is a functional component of the cardiovascular system that plays an important role in health and disease. Injury or dysfunction of endothelium can lead to many forms of cardiovascular disease, and the injured endothelium can serve as a therapeutic target in the prevention and treatment of cardiovascular disease. The cell-based therapies have been shown to alleviate tissue injury and organ dysfunction in animal models of cardiovascular disease. However, clinical trials with cell therapy for patients with cardiovascular disease have yielded inconsistent results and modest benefit overall. A major unsolved problem for cell-based therapy is how to home transplanted cells to damaged organs to improve their survival and to enhance tissue repair and organ function. We have developed an innovative strategy to overcome this hurdle by intravenously transfusing rat endothelial cells overexpressing the neutrophil interleukin-8 (IL-8) receptors IL8RA and IL8RB into rats with experimental endoluminal injury of the carotid artery. We have shown that, equipped with the IL8R homing device, endothelial cells mimic the behavior of neutrophils and compete with the binding of neutrophils to IL-8 overexpressed in injured vessels, thus inhibiting the neutrophilinduced inflammatory response and accelerating reendothelialization and vascular repair. This targeted delivery of endothelial cells to sites of cardiovascular injury provides a novel therapeutic strategy for cardiovascular disease. The results of the present study open the door to new therapeutic applications of cell therapy in patients with cardiovascular injury.
Conclusions-Endothelial cells (ECs) with overexpression of IL8RA
and/or IL8RB mimic the behavior of neutrophils that target and adhere to injured tissues, preventing inflammation and neointima formation. Targeted delivery of ECs to arteries with endoluminal injury provides a novel strategy for the prevention and treatment of cardiovascular disease. 24
MicroRNA-21 Integrates Pathogenic Signaling to Control Pulmonary Hypertension: Results of a Network Bioinformatics Approach
Summary-Pulmonary hypertension (PH) is a deadly disease with diverse etiologies resulting in pathological dysregulation in the pulmonary vasculature. This dysregulation involves numerous intersecting signaling pathways, the coordinate control of which may depend on master molecular effectors. MicroRNA molecules (miRNA) are small, noncoding RNA that may act as such regulators, but their importance in PH is still unclear. In the present study, a unique network biologybased approach was used to identify microRNA-21 (miR-21) as 1 of a select group of miRNA predicted to control expression of a convergent set of pathways in PH. Underscoring the biological plausibility of this finding, miR-21 is upregulated by hypoxia and bone morphogenetic protein receptor 2 signaling, 2 important PH triggers. In turn, miR-21 targets an important vascular effector, RhoB, and induces molecular changes in pulmonary endothelial cells consistent with vasodilation and decreased angiogenesis. Furthermore, miR-21 is upregulated in lung from humans with PH and from multiple rodent models of PH. In 1 of these models, the genetic absence of miR-21 causes accelerated disease progression. Taken together, these data identify miR-21 as a coordinate regulator of PH pathology that acts as a homeostatic brake to stave off PH progression. This study reinforces the critical role for miRNA in PH and introduces the utility of a network-based method for identifying additional groups of disease-modifying miRNA. Because complex interactions among these miRNA with their common targets will dictate their individual impact on disease, the study of such miRNA networks may offer insight into their utility as therapeutic targets.
Conclusions-A network-based bioinformatic approach coupled with confirmatory in vivo data delineates a central regulatory role for miR-21 in PH. Furthermore, this study highlights the unique utility of network biology for identifying disease-modifying microRNA in PH. 25
Ischemic Conditioning Protects the Uremic Heart in a Rodent Model of Myocardial Infarction
Summary-Ischemic conditioning encompasses a number of established experimental techniques that provide powerful protection for an organ or vascular bed against ischemia/reperfusion injury. However, by and large, clinical trials have not delivered on the promise of preclinical studies undertaken in animals. A number of comorbid conditions such as diabetes mellitus and dyslipidemia have been demonstrated in animal models to attenuate the efficacy of ischemic conditioning. Up to one third of patients presenting with an acute coronary syndrome have chronic kidney disease. These patients have a particularly poor prognosis after acute myocardial infarction that has not been improved by enhanced reperfusion rates. Moreover, patients with chronic kidney disease are frequently excluded from clinical trials. The present study demonstrates that renal dysfunction per se is not a barrier to achieving substantial myocardial protection with ischemic preconditioning, remote ischemic preconditioning, and ischemic postconditioning. The survival pathways thought to be important in transducing the protective effect of ischemic preconditioning, remote ischemic preconditioning, and ischemic postconditioning appear to be preserved and activated to the same degree in 2 different models of experimental renal failure. This study provides the preclinical data to justify the inclusion of patients with chronic kidney disease in future clinical trials of ischemic conditioning as adjuvant therapy to reperfusion in the setting of acute myocardial infarction.
Conclusions-Conditioning strategies may present the best opportunity to improve outcomes for patients with chronic kidney disease after an acute coronary syndrome. 26
Rheb is a Critical Regulator of Autophagy During Myocardial Ischemia: Pathophysiological Implications in Obesity and Metabolic Syndrome
Summary-The incidence of heart failure after acute myocardial infarction (MI) remains very high in patients. This highlights the necessity to clarify the mechanism regulating the survival and death of cardiomyocytes in response to ischemia and to find new cardioprotective therapies reducing ischemic injury. We discovered that Rheb, a small GTP-binding protein, plays a pivotal role in regulating the survival of cardiomyocytes during prolonged myocardial ischemia. Rheb activity is reduced in the ischemic heart, thereby causing the suppression of the mTORC1 pathway. Inhibition of the Rheb/ mTORC1 pathway is an adaptive response during ischemia, because forced restoration of cardiac Rheb activity is detrimental under this condition. Rheb inhibition is required for the activation of autophagy, an intracellular degradation process for proteins and organelles, which is protective during energy stress through preservation of cellular energy and relief of ER stress. We discovered that obesity and metabolic syndrome (Ob/MS) are associated with cardiac activation of Rheb/mTORC1 at baseline and during ischemia. In obese mice, autophagy in the heart was suppressed and ischemic injury was exacerbated. Remarkably, inhibition of mTORC1 restores autophagy and reduces infarct size in these animals after prolonged ischemia. Thus, our results suggest that Rheb and mTORC1 may be promising therapeutic targets to reduce myocardial damage after prolonged ischemia in patients with Ob/MS who display deregulated activation of the Rheb/TORC1 pathway and consequent inhibition of autophagy.
Conclusions-Inactivation of Rheb protects cardiac myocytes during energy deprivation through activation of autophagy. Rheb and mTORC1 may represent therapeutic targets to reduce myocardial damage during ischemia, particularly in obese patients. 27
Blockade of the Nuclear Factor-κB Pathway in the Endothelium Prevents Insulin Resistance and Prolongs Life Spans
Summary-Insulin resistance is an important mechanism underlying obesity-related disorders, eg, diabetes, hyperlipidemia, and hypertension, collectively called the metabolic syndrome. In particular, inflammation and oxidative stress are well known to play important roles in the pathogenesis of this systemic syndrome and the resultant development of atherosclerosis. A transcription factor, nuclear factor-κB (NF-κB), has been considered to mediate the responses to both inflammation and oxidative stress intracellularly. However, the site(s) at which the NF-κB signaling pathway plays critical roles in these pathological processes remains to be elucidated. This study focused on the roles of endothelial NF-κB signaling. By expressing the dominant-negative IκB mutant in the endothelium using the transgenic procedure, the NF-κB signaling pathway was blocked selectively in endothelial cells. These mice were protected from the development of both obesity-and age-related insulin resistance. Furthermore, importantly, these mice exhibited prolonged lifespans. In addition to the decrease in relatively early deaths, maximum lifespan was shown to be longer in these transgenic mice. Vascular senescence was markedly inhibited by blockade of endothelial NF-κB. Thus, the endothelium plays important roles in obesity-and age-related disorders through intracellular NF-κB signaling, ultimately impacting lifespan. Blockade of endothelial NF-κB signaling apparently protects the whole body from both fatal morbidities at earlier ages and the development of senescence. Amelioration of insulin resistance and decreased oxidative stress are likely to contribute to these beneficial phenotypes. Therefore, endothelial NF-κB signaling is a potential target not only for treating the metabolic syndrome, but also for antiaging strategies.
Conclusions-The endothelium plays important roles in obesity-and age-related disorders through intracellular NF-κB signaling, thereby ultimately affecting life span. Endothelial NF-κB signaling is a potential target for treating the metabolic syndrome and for antiaging strategies. 28
C/EBP Homologous Protein-10 (CHOP-10) Limits Postnatal Neovascularization Through Control of Endothelial Nitric Oxide Synthase Gene Expression
Summary-Understanding the molecular and cellular mechanisms involved in the regulation of vessel growth and maturation in the setting of tissue ischemia is of major importance and may trigger the development of innovative strategies of therapeutic angiogenesis in the treatment of ischemic diseases. In the present study, we analyzed the role of C/EBP homologous protein-10 (CHOP-10) in postischemic revascularization. CHOP-10 is a novel developmentally regulated nuclear protein that emerges as a critical transcriptional integrator among pathways regulating differentiation, proliferation, and survival. This study identifies CHOP-10 as a major modulator of vessel formation and maturation. The physiological significance of CHOP-10 in the vasculature is validated by the observation that ischemia and diabetes mellitus-induced oxidative stress upregulated CHOP-10 levels and that CHOP-10 deficiency markedly improved postischemic vessel growth in control animals but also in a pathological setting, such as diabetes mellitus. Finally, our data demonstrated that the transcriptional repression of endothelial nitric oxide synthase by CHOP-10 greatly contributes to the antiangiogenic effects of CHOP-10. In conclusion, this work suggests that CHOP-10 functions as an important regulator of postnatal neovascularization. Because downregulation of CHOP-10 promoted neovascularization, the regulation of CHOP-10 expression and activity may pave the way for new therapeutic strategies designed to increase vessel growth in the setting of ischemia. In contrast, forced expression or activation of CHOP-10 might limit unwanted neovascularization associated with tumor development or retinopathy.
Conclusions-This study identifies CHOP-10 as an important transcription factor modulating vessel formation and maturation. 29
Coronary Vasospasm Induced in Transgenic Mouse With Increased Phospholipase C-δ1 Activity
Summary-Coronary spasm is involved in the pathogenesis of not only variant angina, but the other acute coronary syndromes; however, its precise mechanism still remains unclear. We reported that phospholipase C (PLC)-δ1 activity in cultured skin fibroblasts obtained from patients with coronary spastic angina (CSA) was increased 3-fold compared with that from control subjects. We also detected R257H variant PLC-δ1 in CSA patients, which was associated with the increased PLC-δ1 enzymatic activity. We further found that p122 protein, a positive regulator of PLC-δ1, was upregulated in CSA patients. Thus, the increased PLC-δ1 activity caused by either structural mutation or increased positive regulator is likely to be related to the pathogenesis of coronary spasm. However, there has been no proof for a direct contribution of increased PLC-δ1 to enhanced coronary vasomotility. In this study, we generated transgenic mice with increased PLC-δ1 activity in vascular smooth muscle cells by overexpressing human R257H variant PLC-δ1. Our transgenic mouse showed increased PLC enzymatic activity in the coronary artery and enhanced coronary vasoconstrictor response to ergometrine compared with the wild-type mouse. In particular, intravenous ergometrine administration induced ST elevation on ECG and focal coronary artery narrowing such as that seen in CSA patients in the transgenic but not in the wild-type mouse. Thus, this transgenic mouse is a novel animal model of CSA and would provide a novel tool for revealing the mechanism for coronary spasm and investigating the treatment of CSA.
Conclusions-Increased PLC-δ1 activity enhances coronary vasomotility such as that seen in patients with coronary spastic angina. 30
Gene Inactivation of Proprotein Convertase Subtilisin/Kexin Type 9 Reduces Atherosclerosis in Mice
Summary-The proprotein convertase subtilisin/kexin type 9 (PCSK9) promotes the degradation of the low-density lipoprotein receptor and hence is a promising target to treat hypercholesterolemia and to prevent cardiovascular diseases. Clinical trials are currently under way to determine whether inhibiting PCSK9 is a safe and efficient approach in humans. The present study demonstrates for the first time that the absence of PCSK9 protects both wild-type and apolipoprotein E-deficient mice from atherosclerosis. This protection is dependent on the low-density lipoprotein receptor because the correlation between PCSK9 and atherosclerosis was lost in lowdensity lipoprotein receptor-deficient mice. Our data thus suggest that PCSK9 inhibition will be beneficial in reducing the development of atherosclerosis. In view of the selectivity of action of PCSK9 on the low-density lipoprotein receptor in the liver and possibly in the small intestine, it is expected that drugs that would target PCSK9 will exhibit fewer side effects than those related to statins.
Conclusions-Altogether, our results show a direct relationship between PCSK9 and atherosclerosis. PCSK9 overexpression is proatherogenic, whereas its absence is protective. 31 
9-Cis Retinoic Acid Promotes Lymphangiogenesis and Enhances Lymphatic Vessel Regeneration: Therapeutic Implications of 9-Cis Retinoic Acid for Secondary Lymphedema
Summary-Lymphedema, or tissue swelling, is caused by abno rmal tissue fluid accumulation resulting from lymphatic malformation or secondary lymphatic disruption resulting from lymph node dissection, irradiation, or parasite infection. Lymphedema is a disfiguring and painful illness and often is associated with tissue fibrosis and recurrent infection, thus significantly compromising patients' quality of life. Although hundreds of millions of people worldwide suffer from lymphedema in their lower extremities as a result of parasite infection, cancer survivors are the most common lymphedema patients in the United States because lymph node dissection and radiation therapies essentially obstruct the lymphatic function. Although the sentinel lymph node biopsy reduces the prevalence of lymphedema, the number of lymphedema patient is increasing as the cancer survival rate increases. However, effective treatments against lymphedema are not available beyond physical therapies. Therefore, our finding of the therapeutic efficacy of retinoic acids for experimental lymphedema presents an important breakthrough in the treatment of this disfiguring disease. Retinoic acids especially have been characterized extensively for their medicinal properties and thus can be implemented immediately in clinics. Our in vitro and animal studies demonstrate the prolymphangiogenic efficacy of retinoic acids and suggest that retinoic acids could be developed as an effective therapeutic agent to cure secondary lymphedema.
Conclusions-These in vitro and animal studies demonstrate that 9-cisRA potently activates lymphangiogenesis and promotes lymphatic regeneration in an experimental lymphedema model, presenting it as a promising novel therapeutic agent to treat human lymphedema patients. 32
Human Embryonic and Induced Pluripotent Stem Cell-Derived Cardiomyocytes Exhibit Beat Rate Variability and Power-Law Behavior
Summary-Atrioventricular conduction block and arrhythmias caused by sinoatrial node dysfunction are generally treated with electronic pacemakers. Although an excellent therapy, electronic pacemakers incorporate limitations that have stimulated research on biological pacing. Initial proof of concept has been followed by attempts to optimize biological pacemakers so that their function of generating stable basal rates and brisk autonomic responses is manifested over long intervals. Importantly, the functional features of the prototypical biological pacemaker, the sinoatrial node, are not limited to automaticity. Rather, the normal node has an organized rhythm that is stable over time, imposes a dominant rhythm on the cardiac substrate, and has autonomic responsiveness. Hence, it is likely desirable that at least a subset of fabricated biological pacemakers would function much like the sinoatrial node. To achieve this, we need additional understanding of the intrinsic firing patterns of cell types proposed for use as biological pacemakers with the sinoatrial node as an operational standard. To this end, we recorded extracellular electrograms from human embryonic and induced pluripotent stem cell-derived cardiomyocytes, and the beat rate time series of the spontaneous activity were examined in terms of power spectral density and additional methods derived from nonlinear dynamics. In brief, we demonstrated that human embryonic and induced pluripotent stem cell-derived cardiomyocytes exhibit beat rate variability and power-law behavior as in humans, thus supporting the potential capability of these cell sources to serve as biological pacemakers.
Conclusions-This is the first study demonstrating that human embryonic stem cell-derived cardiomyocytes and induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs) exhibit beat rate variability and power-law behavior as in humans, thus supporting the potential capability of these cell sources to serve as biological pacemakers. Our ability to generate sinoatrial-compatible spontaneous cardiomyocytes from the patient's own hair (via keratinocyte-derived iPSCs), thus eliminating the critical need for immunosuppression, renders these myocytes an attractive cell source as biological pacemakers. 33
Proteomics Analysis of Cardiac Extracellular Matrix Remodeling in a Porcine Model of Ischemia/Reperfusion Injury
Summary-By diverging from the traditional focus on intracellular proteins, we used a conceptually novel proteomics approach in which newly synthesized matrix proteins or loosely bound factors in the extracellular space were analyzed before the tissues were decellularized and integral extracellular matrix components were solubilized, which are not dissolved in conventional extraction buffers. By using this extraction procedure combined with state-of-the-art proteomics, we revealed novel extracellular matrix components in cardiac tissue and gained important insights into extracellular matrix remodeling by region and stage of fibrosis. Unlike any other proteomics study published to date, this extensive comparison allowed, for the first time, a coexpression analysis of extracellular matrix remodeling in a porcine model of myocardial ischemia/reperfusion injury. This biosignature of early-and late-stage remodeling may have clinical utility as prognostic markers. The novel extracellular matrix components identified in this study, and particularly those involved in the TGFβ regulatory pathway, may represent interesting modifiable targets for drug discovery.
Conclusions-Our findings reveal a biosignature of early-and latestage extracellular matrix remodeling after myocardial ischemia/ reperfusion injury, which may have clinical utility as a prognostic marker and modifiable target for drug discovery. 34
The Bispecific SDF1-GPVI Fusion Protein Preserves Myocardial Function After Transient Ischemia in Mice
Summary-Heart failure is the major serious complication of myocardial infarction. Circulating bone-marrow-derived stem cells play a critical role in repair mechanisms of infarcted myocardium and limit disease progression and heart failure. Clinical trials suggest that regenerative mechanisms of the diseased myocardium can be supported by administration of autologous bone-marrow-derived stem cells. One major limitation of the stem cell-based treatment option is low and undirected accumulation of cells with high regenerative potential at the site of injured myocardium. Bifunctional recombinant molecules that target both structures of the diseased myocardial microcirculation and distinct circulating bone-marrow-derived stem cells such as SDF1-GPVI have been shown to be of great potential to augment peripheral recruitment of stem cells toward diseased myocardium. These molecules have been proven to limit heart failure and preserve myocardium in disease-related mouse models. These molecules may be a promising strategy to promote myocardial repair and to preserve cardiac function after myocardial infarction.
Conclusions-These results indicate that administration of SDF1-GPVI may be a promising strategy to treat myocardial infarction to promote myocardial repair and to preserve cardiac function. 35
Identification of a Monocyte-Predisposed Hierarchy of Hematopoietic Progenitor Cells in the Adventitia of Postnatal Murine Aorta
Summary-Leukocytes play diverse and critical roles in vascular biology and disease, including the development and progression of atherosclerosis. The source of leukocytes in the vascular wall has generally been considered to be remote tissues such as bone marrow or spleen via the peripheral circulation. This article presents new evidence that demonstrates that mature murine arteries contain resident stem and progenitor cells that are capable of forming hematopoietic colonies in culture and repopulating different types of blood cells after whole-body irradiation. These hematopoietic populations are strongly skewed toward monocyte/macrophage and lymphocyte lineages and are notably upregulated in proatherogenic mice. They are contained primarily among adventitial cells that express stem cell antigen-1, where they may be resident for prolonged periods, perhaps even constitutively. The presence of such stem and progenitor cells in the arterial adventitia provides a new paradigm to support the local origins of vascular leukocytes, in turn paving the way for a greater understanding of the regulation and involvement of inflammatory cells during vascular responses to acute and chronic injury. Ultimately, defining the role of these cells in human arteries in both health and disease may also provide new therapeutic opportunities to affect the evolution of different vascular disease processes, including atherosclerosis, aneurysm formation, vasculitis, ischemia, and malignancy.
Conclusions-The postnatal murine aorta contains rare multipotent hematopoietic progenitor/stem cells and is selectively enriched with stem cell antigen-1-positive monocyte/macrophage precursors. These populations may represent novel, local vascular sources of inflammatory cells. 36 e98 Circulation August 13, 2013
Notch Activation of Jagged1 Contributes to the Assembly of the Arterial Wall
Summary-Notch signaling is an evolutionarily conserved pathway that has been implicated in several forms of congenital heart disease and vascular pathologies. Alagille syndrome, a multisystem disorder associated with mutations in the Notch2 receptor or the Notch ligand Jagged1, results in both cardiac defects such as pulmonary artery stenosis and tetralogy of Fallot and a variety of vascular lesions. These vascular lesions may be the result of defective smooth muscle development. The vascular smooth muscle of the aortic arch arteries provides for the eventual smooth muscle of much of the mature cardiac outflow tract and is derived from neural crest cells. In this article, we demonstrate a critical role for an autoamplification of Notch signaling in cardiac neural crest during vascular smooth muscle development. Notch activation, mediated by endothelial Jagged1, stimulates smooth muscle differentiation of undifferentiated mesenchyme to become vascular smooth muscle. This smooth muscle differentiation is accompanied by an upregulation of Jagged1 expression that activates Notch in subsequent neural crest cells. This lateral induction is mediated by a newly identified enhancer within the Jagged1 genomic locus, demonstrating that Jagged1 is a direct transcriptional target of Notch in vascular smooth muscle. Interruption of this signaling loop, through inhibition of Notch signaling or deletion of the Jagged1 receptor in the neural crest, results in reproducible forms of congenital heart disease involving the outflow tract of the heart. The elucidation of Jagged1 and Notch regulation during smooth muscle development will aid our understanding of congenital abnormalities and vascular defects associated with Jagged1/Notch deficiencies.
Conclusions-Taken together, these results provide a mechanism for lateral induction that allows for a multilayered smooth muscle wall to form around a nascent arterial endothelial tube and identify Jagged1 as a direct Notch target. 37
Safety and Efficacy of Allogeneic Cell Therapy in Infarcted Rats Transplanted With Mismatched Cardiosphere-Derived Cells
Summary-Cardiosphere-derived cells (CDCs) are an attractive cell type for cardiomyoplasty after myocardial infarction, and autologous CDCs are already being tested clinically in the CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction (CADUCEUS) trial. Autologous therapy avoids immunologic rejection but necessitates patient-specific tissue harvesting, cell processing, and quality control, resulting in 3-to 6-week delays to therapy and possible variations in cell potency related to patient age and comorbidities. The use of universal donor (allogeneic) cells, if safe and effective, would obviate such limitations; however, immune rejection may limit effectiveness regardless of whether it poses safety hazards. Thus, we compared syngeneic and allogeneic CDC transplantation in infarcted rats from immunologically mismatched inbred strains. We demonstrate that allogeneic CDC therapy without immunosuppression is safe and induces only a mild transient local response without signs of systemic immunogenicity. Despite lower long-term engraftment compared with syngeneic cells, allogeneic CDCs produce similar structural and functional beneficial effects (which persist at least 6 months after transplantation). The benefits are due to stimulation of endogenous repair mechanisms and regrowth of recipient heart tissue rather than formation of new donor-derived myocardium. In practice, the present work opens up a new treatment paradigm: CDCs could be grown in large numbers from allogeneic heart tissue in a central facility under strict quality control and banked for future use, enabling safe and effective myocardial repair in a timely, cost-efficient manner.
This work motivates the testing of allogeneic human CDCs as a potential clinical product for cellular cardiomyoplasty.
Conclusions-Allogeneic CDC transplantation without immunosuppression is safe, promotes cardiac regeneration, and improves heart function in a rat myocardial infarction model, mainly through stimulation of endogenous repair mechanisms. The indirect mechanism of action rationalizes the persistence of benefit despite the evanescence of transplanted cell survival. This work motivates the testing of allogeneic human CDCs as a potential off-the-shelf product for cellular cardiomyoplasty. 38
Multipotent Vasculogenic Pericytes From Human Pluripotent Stem Cells Promote Recovery of Murine Ischemic Limb
Summary-In this study, we have generated for the first time a novel population of vasculogenic pericytes with multipotent mesodermal features, which is derived from human pluripotent embryonic and induced stem cells. The scalability of human pluripotent stem cells together with the stable phenotype of the highly expandable pericytic derivatives fulfills the demand for sufficient cell quantities for potential autologous clinical transplantation. Our findings support the notion that human pluripotent stem cell pericytes can be generated alongside with vascular endothelial cells from the same source of human pluripotent stem cells in a batch-to-batch consistent manner to treat ischemic diseases and potentially cardiovascular disorders, as well. Additional possible therapeutic applications include syndromes with use of pericytes derived from normal or disease-carrying human pluripotent stem cells to study disease modeling and drug screening, pericyte abnormalities such as hemangiopericytoma, diabetic retinopathy, and Alzheimer disease.
Conclusions-Derivation of vasculogenic and multipotent pericytes from hPSC can be used for the development of vasculogenic models using multiple vasculogenic cell types for basic research and drug screening and can contribute to angiogenic regenerative medicine. 39 
